This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Moderna‘s (NASDAQ: MRNA) success story is all about its coronavirus vaccine. The product generated a whopping $1.7 billion in revenue in the first quarter and brought the company its first ever quarter of profitability. This is big — especially considering Moderna didn’t have any commercialized products until regulators authorized the vaccine in late December.

Investors are hoping this is just the beginning of Moderna’s coronavirus vaccine revenue growth. It should be. Experts say the virus is here to stay. And Moderna is ramping up to produce 3 billion doses next year. But one threat to revenue could be on the horizon. And it has to do with the potential waiving of vaccine patent protection. But is this really a threat? Let’s take a closer look.

A controversial proposal

This week, the U.S. said it would support a controversial proposal to waive vaccine patent rights to ramp up the production of doses globally. Now, all World Health Organization members must weigh in on the issue. Meanwhile, shares of Moderna slipped 8.6% this past week. Some investors were concerned that a potential approval of such a proposal would hurt Moderna’s ability to generate future revenue from its vaccine.

From an intellectual-property point of view, waiving patent rights may set an unwanted (at least by healthcare companies and their shareholders) precedent. That’s because it may make it easier for countries to repeat the move in the future. And in some cases, that could weigh on a company’s ability to generate revenue from a product.

But the Moderna story is a bit different. Here’s why: Moderna could easily hand over instructions to make its mRNA vaccine. In fact, last fall the company said it wouldn’t enforce its COVID-19 patents during the pandemic.

But this doesn’t mean anyone else can actually produce the vaccine. Imagine trying to make your grandmother’s signature cake recipe. But you don’t have access to the key ingredients, the right pan, or even a proper oven. That’s similar to the situation of potential vaccine makers if they hope to replicate the Moderna vaccine.

The CEO comments

In Moderna’s earnings report on Thursday, CEO Stephane Bancel said a possible waiver “doesn’t change anything for Moderna” and added:

There is no mRNA in manufacturing capacity in the world. This is a new technology. You cannot go hire people who know how to make the mRNA. Those people don’t exist.

Bancel is right. The skilled workers, the manufacturing processes and equipment, and the production scale-up are roadblocks potential producers are unlikely to move past. And even if a rival decided to dive in and give it a try, the effort would take an extraordinary amount of time and money. That’s because Moderna’s original effort took a lot of time and money too.

Moderna may look like an overnight success. After all, it brought the coronavirus vaccine to market in about nine months. But the company has been working on mRNA technology for years. And government investment of $2.5 billion wasn’t just an order for doses. Some of the funds helped Moderna develop the vaccine and build up manufacturing capacity over the past year.

So, for a patent waiver to actually hurt Moderna, governments would have to help potential vaccine makers by investing in manufacturing facilities and raw material production. They would have to help companies create processes and train workers. It seems very unlikely such a scenario will play out.

The potential patent waiver isn’t a threat to the Moderna vaccine. Whether it’s approved or not, Moderna is likely to remain in control of its product well into the future. And from what we can see so far, Moderna’s vaccine profit prospects remain strong. The company is in discussions for 2022 orders with all countries that ordered vaccines this year. And all of this means investors shouldn’t worry about any dips in the biotech company’s share price related to vaccine waiver news.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Moderna just made the Pfizer vaccine’s biggest weakness an even bigger one
• 4 healthcare share tips from a fundie with a health PhD

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Should you worry about this threat to Moderna’s vaccine? appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3hfrBML

Motley Fool Australia Chief Investment Officer Scott Phillips joined Weekend Sunrise on Sunday to discuss why (some) inflation can be a good thing, the steady pre-Budget leaks, and what the ATO will be watching out for this tax time…

https://fast.wistia.com/embed/medias/oq9rm742rp.jsonphttps://fast.wistia.com/assets/external/E-v1.js

More reading

• Woolworths (ASX:WOW) share price rises on Endeavour demerger update
• Incitec Pivot (ASX:IPL) share price sinks 7% on Waggaman update
• Why the Bubs (ASX:BUB) share price is down 5% to a multi-year low
• Dogecoin loses nearly a third of its value after Elon Musk called it a “hustle” on comdy show
• Telix (ASX:TLX) share price on watch amid clinical trial news

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post RBA looks for inflation, the government is about to spend big, and the ATO is watching: Motley Fool CIO Scott Phillips on Weekend Sunrise appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/33tWUvp

The Woolworths Group Ltd (ASX: WOW) share price is on the move on Monday morning.

At the time of writing, the retail conglomerate’s shares are up 1.5% to $40.00.

Why is the Woolworths share price rising?

Investors have been buying the company’s shares following the release of an update on its Endeavour Group plans.

According to the release, the Woolworths board has determined that a demerger is likely to enhance shareholder value over time and is preferable to other available options.

The company notes that the proposed demerger is the final step in a process that involves the combination of Woolworths Group’s drinks and hospitality businesses to form Endeavour Group through a restructure of Endeavour Drinks and subsequent merger with ALH Group.

What now?

If approved and implemented, the demerger will create two independent and leading ASX-listed companies.

Woolworths Group shareholders will retain all their existing Woolworths Group shares, with eligible shareholders receiving one new Endeavour Group share for every Woolworths Group share held at the demerger record date.

The company and its long-term joint venture partner, Bruce Mathieson Group, will each hold a 14.6% interest in Endeavour Group at the time of the demerger.

Woolworths Group’s directors are unanimously recommending that shareholders vote in favour of the proposed demerger resolutions. All directors intend to vote their own shares in favour of the demerger. An Independent Expert, Grant Samuel, has also concluded that the demerger is in the best interests of shareholders.

The company’s Chairman, Gordon Cairns, said: “The Woolworths Group Board believes that a demerger of Endeavour Group will enhance shareholder value and it will create two leading ASX-listed companies. We believe both businesses, post demerger, have strong future prospects and will benefit from greater simplicity, focus and ongoing partnership.”

What will Endeavour Group look like?

The release advises that the demerger is intended to enable Endeavour Group to realise its full potential with a clear purpose across Retail, Hotels and its broader business.

Post demerger, Endeavour Group will have an independent business strategy and a broad mandate for growth. It will also have the capacity and access to capital to pursue a range of investment and growth initiatives.

On a pro forma basis, Endeavour Group reported FY 2020 sales of $10.6 billion, EBIT of $693 2 million, and net profit before significant items of $328 million.

It has committed bank facilities of $2.5 billion with net debt (before lease liabilities) of $1.4 billion to $1.5 billion expected at the time of demerger. The bank facilities will be used to repay inter-company borrowings with Woolworths Group, and provide sufficient liquidity to support Endeavour Group’s funding requirements.

Like Woolworths, Endeavour Group will be sharing its profits with shareholders. It intends to follow Woolworths Group’s long established dividend policy which is initially expected to deliver a payout ratio of 70% to 75% of profit.

Endeavour Group CEO, Steve Donohue, said: “We believe that Endeavour Group’s long-term prospects are strong. We have assembled an experienced and proven team, have a leading store network, digital presence, and market position. Through living our purpose of creating a more sociable future together we see many opportunities to grow the business and create value for our shareholders.”

More reading

• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• Wrong… but still right!
• 2 fantastic blue chip ASX 200 shares rated as buys
• Vicinity (ASX:VCX) sees improvements as it struggles back to COVID-normal
• ASX 200 Weekly Wrap: Shares have average week but a great month

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Woolworths Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Woolworths (ASX:WOW) share price rises on Endeavour demerger update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3xSaYN8

The Incitec Pivot Ltd (ASX: IPL) share price has come under pressure on Monday morning.

At the time of writing, the industrial chemicals company’s shares are down almost 7% to $2.51.

Why is the Incitec Pivot share price under pressure?

Investors have been selling Incitec Pivot’s shares following a further update on the Waggaman ammonia plant.

Last month the company revealed that the recommencement of operations at Waggaman was being disrupted due to issues with a dry gas seal failure and vibrations in the turbine.

At that point, it warned that the delay would impact its earnings before interest and tax (EBIT) by $36 million.

What’s the latest?

According to today’s update, the Waggaman plant re-started again in the middle of April as expected.

It was operating successfully at nameplate capacity for a total of two weeks before the plant unexpectedly tripped upon the failure of a vibration probe.

Following repairs, the subsequent re-start process was stopped on 8 May due to a coupling failure on the refrigeration compressor, upon which the plant was safely shutdown.

Management advised that bringing the Waggaman plant back to full operation is its highest priority, with all appropriate internal and external resources being deployed to achieve this.

Earnings impact

The release explains that based on current information, repairs and re-start are expected to take two to three weeks.

The additional impact to FY 2021 EBIT from the initial trip to the expected re-start of the plant is estimated to be between $33 million and $42 million. This represents between $26 million and $33 million on a net profit after tax basis.

In all other respects, Incitec Pivot’s business performance remains in line with previous update.

Despite today’s decline, the Incitec Pivot share price is still up a solid 11% since the start of the year.

More reading

• Why the Incitec (ASX:IPL) share price is in the spotlight today
• Looming grocery price shock to impact on these ASX shares
• ASX 200 Weekly Wrap: ASX sees 7,000 points once more

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Incitec Pivot (ASX:IPL) share price sinks 7% on Waggaman update appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/33v1Gc4

The Bubs Australia Ltd (ASX: BUB) share price is sinking on Monday morning.

In early trade, the infant formula company’s shares are down 5% to a multi-year low of 35.5 cents.

This latest decline means the Bubs share price is now down 40% year to date.

Why is the Bubs share price sinking?

Investors have been heading to the exits this morning following the release of an update from one of its larger rivals.

Earlier today, A2 Milk Company Ltd (ASX: A2M) downgraded its FY 2021 guidance for the umpteenth time due largely to weakness in the daigou channel and significant inventory issues.

It is now targeting revenue of NZ$1.2 billion to NZ$1.25 billion for FY 2021 with an earnings before interest, depreciation and amortisation (EBITDA) margin of 11% to 12% (excluding MVM transaction costs). At the mid point of its guidance range, this will be EBITDA of NZ$140 million, down 74.5% on FY 2020’s result.

This compares to its previously downgraded guidance of revenue of NZ$1.4 billion and an EBITDA margin of 24% to 26% (excluding acquisition costs). It is also a long way from its original guidance of “strong revenue growth” and an EBITDA margin of 30% to 31%.

Unfortunately, management warned that it could take some time to rebalance inventory levels and restore channel health.

Judging by the performance of the Bubs share price today, this appears to have spooked investors. They may now be concerned that its own recovery could take longer than hoped as well.

Bubs’ appointment

As a result of the above, news that the company has made a new executive appointment has been overshadowed and failed to have a positive impact on the Bubs share price today.

That appointment sees Fabrizio Jorge join the company as its new Chief Operating Officer.

According to the release, Mr Jorge brings 24 years of experience in the global consumer goods and dairy industry. This includes nutritional and specialty milk powders.

Most recently, he was the General Manager for Fonterra Brands for Thailand, Laos & Myanmar. Previously from 2016 through 2020 he held full P&L responsibility for Fonterra Australia’s Ingredients business with sales to over 50 export markets. This followed a long association with Fonterra going back to 2009 covering South East Asia sales, Fonterra’s South America Ingredients operations, and as Product General Manager for nutritional and specialty formulated milk powders based in New Zealand.

More reading

• Top brokers name 3 ASX shares to sell next week
• A2 Milk (ASX:A2M) share price falls as China suspends dialogue
• Leading brokers name 3 ASX shares to sell today
• The ASX’s China problem is getting worse… and quickly
• Why Bubs, IDP Education, ResMed, & Tyro shares are dropping today

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of BUBS AUST FPO. The Motley Fool Australia owns shares of and has recommended A2 Milk. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Bubs (ASX:BUB) share price is down 5% to a multi-year low appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3uLs8de

Holders of dogecoin weren’t laughing as the price of the cryptocurrency tumbled after Elon Musk called it a “hustle” on a US comedy show.

The comment by the Tesla chief executive and crypto evangelist triggered a close to 30% crash in the value of dogecoin to a low of US47 cents.

It had been trading around US65 cents before the show, reported the Australian Broadcasting Corporation.

Dogecoin’s plunge is no laughing matter

Musk, who was impersonating a financial expert on a guest appearance of the highly-rated Saturday Night Live program, “struggled” to explain what dogecoin is.

He was asked this question several times, and each time he replied with simple facts about dogecoin without answering the question.

For instance, one of Musk’s replies was: “It’s the future of currency. It’s an unstoppable financial vehicle that’s going to take over the world”.

The dogecoin hustle is a difficult dance to master

Finally, when fellow cast member Michael Che asked if dogecoin was a “hustle”, Musk said “Yeah, it’s a hustle”.

Here’s another fun fact about dogecoin. It has surged more than 800% over the last month and is now the fourth largest digital currency.

Dogecoin’s market capitalisation is US$73 billion and it hit a high above US73 cents on May 6, according to CoinGecko.com.

Musk is dogecoin’s biggest supporter

Musk contributed to its meteoric rise with his mostly favourable Tweets on dogecoin, which started as a meme.

He’s trying to make it mainstream by accepting dogecoin payment for a trip to the moon aboard his SpaceX rocket.

Foolish takeaway

I think many people understand what cryptos are and can do, but struggle to put a value on the numerous coin offerings in the market.

Dogecoin is just one of many examples and it’s fall comes at a time when the world’s largest and best known crypto, bitcoin, is under pressure.

Talking about falling from grace, the Tesla Inc (NASDAQ: TSLA) share price has come into strife on its own recently.

The market wasn’t impressed with its record March quarter results. While Tesla’s earnings beat consensus expectations, the electric vehicle manufacturer made more money selling bitcoin than it did cars.

More reading

• How shares with massive PE ratios can be cheap
• Appen (ASX:APX) share price: Is the disruptor becoming the disrupted?
• One MASSIVE thing about Tesla and Afterpay that people forget
• This ASX tech ETF might be in the buy zone today. Here’s why
• Tesla boss: ASX lithium shares set to boom

The post Dogecoin loses nearly a third of its value after Elon Musk called it a “hustle” on comdy show appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2R6aimS

The Telix Pharmaceuticals Ltd (ASX: TLX) share price will be in focus today after the company announced its prostate cancer therapy has been approved for stage III clinical trials.

Shares in the company closed last session trading at $3.94.

The biopharmaceutical company’s prostate cancer therapy, TLX591, has been approved for a stage III trial by the Human Research Ethics Committee and the Australian Therapeutic Goods Administration.

TLX591 is designed to help treat those with metastatic prostate cancer.

Let’s take a closer look at the news Telix released this morning.

New stage III clinical trial

Telix shares will be on watch this morning after the company announced it’s now able to begin a phase III clinical trial of its targeted therapy in patients with advanced metastatic castrate-resistant prostate cancer.

The phase III clinical trial, named ProstACT, will be an international, multi-centre, randomised controlled trial.

Those involved in the trial will be patients with prostate specific membrane antigen- (PSMA) expressing metastatic castrate-resistant prostate cancer. TLX591 is said to use PSMA as a target for the therapy.

The ProstACT trial will involve around 390 patients, selected by imaging with Telix’s imaging technique, Illuccix.

The trial will compare standard of care therapies with the same therapies combined with TLX591.

The trial’s primary endpoint is progression-free survival, with its secondary endpoints including overall survival and quality-of-life assessments.

Telix has begun initiating sites for the Australian ProstACT trial. It will add more sites during the second half of 2021, subject to necessary approvals.

According to Telix, prostate cancer is the second most common cancer in men. Around 1.4 million men were diagnosed with prostate cancer last year. Telicx stated the rate of diagnosis is improving, with the highest number of new prostate cancer cases found in the United States, Europe, Australia and New Zealand.

Commentary from management

Telix CEO Dr Christian Behrenbruch commented on the trial’s approval, saying:

The commencement of the ProstACT Phase III study for TLX591 marks a major corporate milestone for Telix that brings the company a step closer to delivering on a major unmet medical need for treatment options in this patient population… TLX591 has demonstrated promising and competitive clinical potential that we believe warrants further confirmation in this second-line disease setting. It is also noteworthy that Telix’s differentiated approach to integrating molecular imaging with PET alongside therapy, enables a comparatively streamlined study that we believe will support efficient patient enrolment and study execution.

Telix Pharmaceuticals share price snapshot

Investors will be hoping today’s news provides a boost for Telix Pharmaceuticals shares. Currently, the Telix share price is 1.75% lower than it was at the start of 2021. Although, the company’s shares have gained around 162% over the last 12 months.

The company has a market capitalisation of around $1.1 billion, with approximately 281 million shares outstanding.

More reading

• The Telix (ASX:TLX) share price is wobbling today
• Top brokers name 3 ASX small cap shares to buy
• Why the Telix (ASX:TLX) share price is storming 5% higher

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Telix (ASX:TLX) share price on watch amid clinical trial news appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/2SDH7bf

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

If you’re on a mission to become a better investor, your secret weapon is closer than you think.

Books and teachers are great, but nothing compares to the sage advice that mothers typically dole out. Although some words may have gone in one ear and out the other, you’ll look back and be able to unravel some of Mum’s lengthy list of do’s and don’ts as precious gems to live by today. And believe it or not, it can be extremely helpful when it comes to investing. 

As a tribute to all the mothers (and mother figures) out there, we’re going down memory lane to extract Mum’s collection of jewels that you can apply on your investing journey.  

1. Don’t fall for FOMO 

Mum probably didn’t use those exact words, but she may have warned you about FOMO (fear of missing out) somewhere down the line. You may have wanted the latest gadgets, apparel, or look because everyone was raving about it. But carrying that mindset always leaves you on the edge of your seat chasing the next big thing. 

This is true even in the investing world. If you’re always hunting for the hottest stock because of FOMO, you may end up being an emotional wreck if things don’t go your way. Instead, take Mum’s advice and focus on having clear goals and a strategy so you’ll never have to worry about missing out on anything. 

2. Don’t buy the first thing you see 

If we all just pressed the buy button when an investing opportunity popped up on our radar, we’d most likely be in a ton of trouble in the markets. Luck could work in your favor, but the downside of an investment decision that you’re clueless about could leave you sweating bullets at night. 

Do what many mums do: compare and proceed with care. They do their due diligence before they purchase products, performing some form of research and comparison analysis to ensure they are getting the best bang for their buck. So before you purchase your next stock, allow this motherly wisdom to replay in your mind. 

3. Create a shopping list 

Mums hardly ever head to the store without a shopping list.

That shopping list was Mum’s version of a watch list. It gives you a point of reference to focus your attention and get familiar with the price movement of assets you are interested in. 

Creating your watch list of stocks can allow your brokerage firm to notify you if there was an increase or decrease in the price of an asset so that you can move accordingly. Most importantly, keeping a list of what you want and tracking the stock activity of a few stocks can help you to be more efficient in the markets. 

4. Think long term 

Mums are often five steps ahead of the game. If Mum ever said no to the candy, piercing, or tattoos, chances are there was a reason behind it. Most often, it was probably just her way of thinking about your future.

Even in the stock market, there will be all types of temptations that come your way — from selling a stock that skyrocketed in value overnight to acquiring the latest penny stock recommendation from your barber. But you have to be able to step back and consider the long-term implications of your investing decisions. You want to think about how your investment decisions can allow you to take advantage of compound interest and maybe even help you to become the millionaire next door. 

5. Be patient 

This may be one of the hardest lessons to digest. Being patient is not as glamorous as instant gratification, but it has the potential to produce sweeter rewards later. 

Mum may have tested our patience when she had presents under the tree that couldn’t be unwrapped until Christmas or when you were prompted to wait to take a course in driving. Now, you’ll have to relive the wait again as you work to build a portfolio that funds your retirement. 

Patience pays off. While your stocks have the potential to grow in value over time, you can also enjoy a recurring stream of income from stocks that pay dividends. 

Give Mum some credit 

When you think about it, a mother figure’s advice can be golden on your investing journey — even if it’s not dressed up in the fancy financial lingo investors use today. Mums touch on the basic principles of investing that you’ll need to achieve financial success: Do your research, develop goals, and be patient enough to see your long-term vision become reality. 

If you ever start to panic as an investor, just think about this timeless advice to keep you going strong. Mums have survived many unexpected situations and thrived. Chances are, you can achieve your investing goals if you keep these words of wisdom in your back pocket. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Why the Cleanaway (ASX:CWY) share price will be in the spotlight today
• The ASX miners caught in the FOMO trade as copper smashed record highs
• Top broker tips REA Group (ASX:REA) share price to rise 20%
• Is good news bad news or is it actually good news?
• What’s happening with the Pointerra (ASX:3DP) share price?

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 5 ways mums are secret investing geniuses appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3bgdhQp

The Cleanaway Waste Management Ltd (ASX: CWY) share price will be one to watch on Monday morning. This follows the waste management company’s announcement of a new appointment to its senior leadership team.

At Friday’s market close, the Cleanaway share price was trading at $2.80.

What did Cleanaway announce?

Cleanaway shares will be in focus this morning after the company advised it has appointed Mark Schubert as its new CEO and managing director.

Mr Schubert’s appointment comes after having served 4 years as integrated gas executive general manager for Origin Energy Ltd (ASX: ORG). Prior to that, he held a number of senior positions over 18 years within the industry.

Management highlighted Mr Schubert’s track record of operating and transforming major assets, including world-class LNG projects and oil refineries.

Cleanaway executive chair Mark Chellew recognised Mr Schubert’s proficiency, saying:

…Mark brings a wealth of senior executive experience, has proven his ability to lead large and complex businesses, and is a strong fit with our strategy and culture.

Mark will work with our executive team to build on the momentum in our business including our recently announced asset acquisitions from Suez.

Incoming CEO and managing director Mr Schubert went on to add:

I am really looking forward to working with the Cleanaway team across Australia that every day deliver essential services to the communities that they serve. Cleanaway is not only a well performing business but excitingly is also ideally positioned to capture emerging waste streams and future re-use opportunities.

The engagement of Mr Schubert will take effect in the new financial year (after 30 June 2021). Mr Chellew will remain as executive chair until then and continues to be supported by chief operating officer Brendan Gill.

While the official leadership change is a couple of months away, Mr Schubert’s announced appointment will make the Cleanaway share price one to watch today.

Cleanaway share price performance

Since May 2020, the Cleanaway share price has been largely moving in circles. The company’s shares, however, took off last month after it provided notice of an acquisition on the Suez business.

Overall, Cleanaway shares are up almost 50% from this time last year and are around 20% higher year to date.

Cleanaway commands a market capitalisation of roughly $5.7 billion, with approximately 2 billion shares outstanding.

More reading

• ASX 200 Weekly Wrap: Shares have average week but a great month
• These were the best performing ASX 200 shares in April
• These were the best performing ASX 200 shares last week
• The Cleanaway Waste (ASX:CWY) share price is at a new 52-week high
• Downer (ASX:DOW) share price may only be at start of a capital return cycle

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Cleanaway (ASX:CWY) share price will be in the spotlight today appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3exyqYi

ASX copper miners will be in the spotlight this morning after the price of the red metal hit a new record high on the weekend.

COMEX copper futures in New York jumped 3.2% to US$4.75 a pound, reported The Wall Street Journal.

That’s above the last peak of US$4.63 per pound during the last commodity super-cycle in early 2011.

Copper poised to break new record highs again

The copper price also broke records on the London Metal Exchange. The price for the commodity for delivery in three months hit US$10,417 a tonne – or US$257 above its previous all-time high set in February 2011.

What’s more, several commodity forecasters believe copper could be heading higher over the next few months.

ASX miners riding on record copper prices

That’s great news for ASX copper miners. The two largest pure-play copper shares on our market are the OZ Minerals Limited (ASX: OZL) share price and Sandfire Resources Ltd (ASX: SFR) share price.

Mining giants like the Rio Tinto Limited (ASX: RIO) share price and BHP Group Ltd (ASX: BHP) share price will also benefit. But copper makes up only a small fraction of their group profits, so they aren’t seen to be the best way to gain exposure to the surging copper price.

What’s driving the copper super-cycle

Among the metals, copper is uniquely placed on the current boom, in my view. This is because the metal is benefiting from both economic growth and the renewable energy transition.

The global economic rebound from massive government stimulus will lift industrial production and construction, which drives copper demand.

Even as countries like India struggle to contain the resurgence of COVID-19, investors are confident that this will not derail the sharp economic rebound around the world.

On the other side of the demand equation, the rise of electric vehicles, solar and wind power are creating a second tailwind.

Copper price forecasts for 2021

There are other metals that are also leveraged to both these thematic, such as nickel. But no other base metals have the same reach as copper. This is why copper is affectionately referred to as “Dr Copper” by the market as it’s a bellwether for the group.

Meanwhile, there may not be enough of the good Doctor to go around. This prompted London-based hedge fund Commodities World Capital LLP to predict that the metal will climb to between $11,500 and $12,000 a tonne in the coming months, reported the WSJ.

Miners have been underinvesting in finding and developing new copper projects, which take years to bring to production.

But this doesn’t mean the rally will be smooth. Markets almost never go up in straight lines. Nonetheless, buoyant copper prices could be with us for some years yet.

More reading

• ASX 200 Weekly Wrap: Bank shares push ASX 200 towards all-time high
• 5 things to watch on the ASX 200 on Monday
• Iron ore price hits another record high as tensions with China increase
• A2 Milk (ASX:A2M) share price falls as China suspends dialogue
• Brokers say “buy” these 3 ASX shares even as they trade near 52-week highs

Motley Fool contributor Brendon Lau owns shares of BHP Billiton Limited, OZ Minerals Limited, Rio Tinto Ltd, and Sandfire Resources Ltd. Connect with me on Twitter @brenlau.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The ASX miners caught in the FOMO trade as copper smashed record highs appeared first on The Motley Fool Australia.

from The Motley Fool Australia https://ift.tt/3heU3ia